Argenx Just Hit a Wall Nobody Saw Coming

Second, argenx's track record had created a kind of invincibility aura. The company's FcRn platform had delivered wins in myasthenia gravis (a neuromuscular disease where rogue antibodies attack the connection between nerves and muscles) and CIDP (a nerve-damaging autoimmune condition). William Blair called Sjögren's "the next potential blockbuster expansion opportunity" for Vyvgart. That opportunity just evaporated.

The Science Behind the Stumble

To understand why efgartigimod might have flopped in Sjögren's, you need to understand what FcRn inhibitors actually do. Think of it like a recycling program for antibodies.

Your body constantly recycles a type of antibody called IgG. A receptor called FcRn (neonatal Fc receptor) grabs IgG molecules and sends them back into circulation instead of letting them get broken down. Drugs like efgartigimod block that recycling, so IgG levels drop. In diseases where harmful IgG autoantibodies are the main villain, this works beautifully.

But Sjögren's disease is more complicated. It involves T-cell activity, B-cell dysfunction, inflammation in glandular tissue, and pathology that isn't purely driven by circulating IgG antibodies. Blocking IgG recycling is like trying to fix a leaky roof by mopping the floor: you're addressing a downstream symptom, not the upstream cause. FcRn inhibitors are essentially IgG-selective tools, and when the disease involves immune mechanisms beyond IgG, the tool doesn't fit the job.

What's Left in the Tank

The good news for argenx investors is that this failure, while painful, doesn't break the company. The pipeline is deep, and several programs are still chugging along.

In myasthenia gravis, the franchise continues to expand. Argenx has been pushing into ocular MG (with the ADAPT OCULUS study), seronegative MG subtypes, and even pediatric patients. These are natural extensions of a proven mechanism in a proven disease.

The company's autoimmune myositis program (the ALKIVIA trial) had Phase 3 results expected around Q3 2026. A Graves' disease registrational study was slated to begin enrollment in 2026. And the ITP program (immune thrombocytopenia, where the body destroys its own platelets) has a key readout expected in the second half of 2026.

Argenx even reported positive celiac disease data on the same day as the Sjögren's failure, which felt a bit like announcing a promotion at a funeral. The timing was awkward, but it did remind investors that the broader platform still has legs.

By year's end, the company expects to have 10 molecules in clinical development across its immunology pipeline, including next-generation assets like ARGX-213 (in Phase 1 clinical development) and ARGX-124 (finishing Phase 1).

The Bigger Picture: FcRn's Boundaries

This failure isn't just an argenx story. It's a signal for the entire FcRn inhibitor class.

Johnson & Johnson is pushing its own FcRn blocker, nipocalimab, across a wide range of autoimmune diseases, including Sjögren's. UCB has rozanolixizumab approved in myasthenia gravis. Immunovant is developing a next-generation FcRn inhibitor called IMVT-1402 with broad autoimmune ambitions. Everyone in this space is trying to expand beyond the neuromuscular sweet spot where FcRn blockers first proved themselves.

The UNITY failure is a cautionary tale for that expansion strategy. Not every autoimmune disease is primarily driven by IgG antibodies, and FcRn inhibitors can't fix what IgG depletion doesn't address. The mechanism has clear boundaries, and Sjögren's appears to sit on the wrong side of that line.

The Investor Takeaway

Analysts were quick to frame the Sjögren's failure as program-specific, not platform-breaking. That distinction matters. Efgartigimod still works in its core indications, the safety profile remains clean, and the rest of the pipeline didn't suddenly become less promising.

But the selloff reflected something real: a recalibration of expectations. Investors had been pricing in Sjögren's as a major future revenue driver, and that bet is now off the table. The question going forward isn't whether argenx's FcRn platform works (it does, in the right diseases). The question is which diseases are the right ones, and whether the market had gotten too optimistic about how far this one mechanism can stretch.

For argenx, the streak of wins is broken. The company now has to prove that its platform can grow without assuming every autoimmune disease will bend to the same approach. That's a harder story to tell, but it's also a more honest one.

The Cancer That Disappeared in Every Single Patient

GSK's dostarlimab just won FDA approval for a specific type of rectal cancer after trial results that stunned the oncology world: a 100% clinical response rate in early cohorts. For eligible patients, it could mean beating cancer without chemo, radiation, or surgery.